National Projects
| Project title: | DEVELOPMENT OF THE FIRST INTERNATIONAL VALIDATED VACCINE AGAINST ANTIBIOTIC-RESISTANT PNEUMONIA. (STOPINFECTIONS) |
|---|---|
| Reference Number: | RTC2019-007058-1 |
| Partners: | VAXDYN S.L. LABORATORIO REIG JOFRE, S.A ACONDICIONAMIENTO TARRASENSE LEITAT INSTITUTO DE SALUD CARLOS III DE MADRID (ISCIII) |
| Funding Agency: | Ministry of Science, Innovation and Universities and the State Research Agency (AEI) funded this project within the Challenges & Collaboration Subprogram, Call 2019. The project is co-funded by the European Union with the aim of promoting technological development, innovation, and quality research. |
| Objetive: | The main objective of the project is to complete the preclinical development and request permission to enter the clinical phase in humans of KAPAVAX, the first universal trivalent vaccine against infections caused by the bacteria Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii, the three highest pathogens priority among antibiotic resistant for the World Health Organization, against which there is no vaccine in the clinical stages of development. |
| Duration: | 2020-2022 |
| Project title: | DEVELOPMENT OF NEW NANOTECHNOLOGICAL THERAPIES FOR FOLLICULAR RELEASE APPLIED TO ALOPECIA (ALOSTOP) |
|---|---|
| Reference Number: | RTC2019-007035-1 |
| Partners: | Laboratorio Reig Jofre S.A. Fundación para la investigación biomédica del Hospital Univ. Ramon Y Cajal Bionos Biotech Fundación Bosch i Gimpera |
| Funding Agency: | Ministry of Science, Innovation and Universities and the State Research Agency (AEI) funded this project within the Challenges & Collaboration Subprogram, Call 2019. The project is co-funded by the European Union with the aim of promoting technological development, innovation, and quality research. |
| Objetive: | The main objective of the project is to bring to an exploratory clinical study an innovative treatment more effective than the current ones for the treatment of alopecia. |
| Duration: | 2020-2023 |
| Project title: | USE OF MUCOADHESIVE POLYMERIC FORMULATIONS FOR THE ERADICATION OF HELICOBACTER PYLORI (PYLOMUC) |
|---|---|
| Reference Number: | RTC-2017-6643-1 |
| Partners: | Laboratorio Reig Jofre S.A. Bionanoplus S.L. Universidad de Navarra Universidad de Sevilla |
| Funding Agency: | Ministry of Science, Innovation and Universities funded this project within the Challenges & Collaboration Subprogram, Call 2017. The project is co-funded by the European Union with the aim of promoting technological development, innovation and quality research.  |
| Objetive: | The main objective of the project is to develop innovative formulations based on mucoadhesive polymeric systems for the treatment of gastric ulcers caused by Helicobacter pylori infection. |
| Duration: | 2018-2021 |
| Project title: | TRANSITION TO CLINICAL INVESTIGATION PHASE FOR LICENSE OF THE FIRST VACCINE AGAINST DRUG RESISTANT ACINETOBACTER BAUMANNII (ACINETOCLINIC) |
|---|---|
| Reference Number: | RTC-2016-5161-1 |
| Funding Agency: | Vaxdyn Laboratorio Reig Jofre SA Draconis Pharma Instituto de Biomedicina de Sevilla (IBIS) Hospital Universitario Virgen del Rocío (HUVR) Centro Tecnológico Leitat |
| Cofinanciación: | Ministerio de Economía y Competitividad, cofinanciado a través de fondos FEDER de la Unión Europea, dentro del programa nacional Retos y Colaboración 2016 de la Agencia Estatal de Investigación, con el objetivo principal de Promover el desarrollo tecnológico, la innovación y una investigación de calidad. |
| Objetive: | Complete the transition to clinical development in humans (Phase I in healthy volunteers) of the first universal vaccine against infections caused by bacteria resistant to Acinetobacter baumannii antibiotics (VxD-001 vaccine). |
| Duration: | 2016-2019 |